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Antigen specific T cells and their ability to respond to antigen challenge, is an essential component of our 
immune system. The in-build complexity and genetic heterogeneity in the antigen recognition molecules, T cell 
receptors on one site and antigen presentation molecules, Major Histocompatibility Complex (MHC) I and II, on 
the other site, provides a challenge for immunologist to get full insight and understanding of T cell recognition 
in health and disease. Here, we discuss the use and development of technologies to gain insight to T cell 
recognition, and the impact of such knowledge on therapeutic development and disease control. 
It is evident that applications related to antigen specific T cells or specific T cell receptors have powerful 
potential in disease eradication. This has been demonstrated in cancer by use of TCR gene modified T cells1,2, in 
infectious disease control through adoptive transfer of virus-specific T cells3,4, and in monitoring responses to 
tolerizing allergen immunotherapy5,6. Additionally, both functional and phenotypic characteristics of antigen 
specific T cells seem to play a crucial role for the therapeutic efficacy of both adoptive T cell transfer strategies7 
and vaccination approaches8,9. In the era of personalized medicine and with the accumulation of numerous 
immunotherapeutic strategies being employed, it is becoming increasingly important to understand the T cell 
mediated responses involved in disease progression or elimination, and to identify biomarkers predictive of 
response to such therapy – potentially based on experimental analyses of T cell recognition. Thus, effective 
strategies for simultaneous analyses of such characteristics are highly desirable, and could provide the bases 
for biomarkers of successful induction of T cell reactivity in various settings.  
 
Identification of T cell targets in different disease settings 
Antigen recognition by T cells through the interaction of T cell receptor with peptide-MHC expressed by 
antigen presenting cells represents a critical step in the initiation of most adaptive immune responses. The 
fundamental cellular, molecular and biophysical basis for the development and roles of antigen-specific T cells 
have been elucidated over decades, primarily through analyses of responses to model antigens and through 
the use of T cell receptor transgenic systems (e.g. 2B4, 5c.c7, OT-1 and 2C) in mice10–14. However, because 
many factors can influence the range and identities of antigens targeted by T cells during natural infections or 
diseases15, the study of antigen-specific T cell responses in humans is particularly challenging. Even for very 
well-studied immunological diseases, knowledge of antigenic determinants and the ability to accurately 
identify relevant antigen-specific T cells are often lacking. Here, we will discuss progress in the study of the 
antigen-specific T cell response for a range of diseases to highlight the unique challenges that each provide, 
especially as it relates to the use of methods that allow for direct identification of the relevant antigen-specific 
cells. Since the first description of multimerized pMHC complexes and their ability to bind and visualize 
antigen-specific T cells by flow cytometry16, much progress has been made using this or other strategies to 
identify antigen-specific T cells in various disease settings9,17. Throughout this perspective, emphasis is placed 
on pMHC multimer-based methods. Although they are not ideal for every situation, and not all HLA types are 
equally suitable for multimer production, they are amenable to multiplexing, which is allowing for an 
increasingly broad, less biased and more precise view of the antigen-specific T cell response (Figure 1).  
 
T cell recognition in cancer 
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In cancer, various proteins that are over –or de-novo expressed in cancer tissues have been described as 
targets for T cell recognition. Early studies on T cell recognition in melanoma patients identified T cell epitopes 
among antigens associated with melanin production, such as MART-1, GP100 and Tyrosinase, and later 
numerous cancer testis (or cancer-germline) were identified as antigenic targets for T cell recognition across 
various tumor types18–20. Both have led to specific, and in some cases successful therapeutic strategies in the 
form of vaccination 21 and adoptive transfer of antigen specific T cells1. It has been shown that tumor 
infiltrating lymphocytes from melanoma patients comprises T cells recognizing a range of these antigens, but 
also that a substantial part of the immune reaction against tumors cannot be described by recognition of these 
shared tumor antigens22,23. More recently, extensive focus has been given to describe T cell recognition of 
epitopes derived from genetic alterations in tumors, as these sequences are completely foreign to the immune 
system, hence the term neoepitopes, and at the same time cancer-specific, they in principle form ideal targets 
for antigen specific targeting of cancer. Several lines of evidence show the importance of such neoantigens in 
tumor eradication following immune therapeutic strategies24–27. However, although mutational load and 
predicted number of neoepitopes provides strong correlates of clinical efficacy of immunotherapy, it has been 
challenging to detect T cells recognizing such neoepitopes in large numbers. Neoepitope specific T cells can be 
detected across different cancer types25,28–39. Tumor foreignness, seems to be a major driver for the efficacy of 
checkpoint inhibition therapy 25,40,41, and while foreignness can have many flavors, the genetic alterations are 
easily mapped even at a personalized level through next-generation-sequencing (NGS), and T cell recognition 
against tumor specific mutations has been identified in many different cancer types 25,28–35. However, there is 
still a huge gap in our understanding of neoepitope recognition in cancer, which should be filled for 
neoepitope-specific targeting to fully meet its expected therapeutic potential27,42. 
Profiling epitope-specific recognition in cancer is challenging based on the nature of cancer 
development and the co-evolution of cancer cells under immunological surveillance.  a) Cancer cells are highly 
heterogeneous, both within a given cancer lesson, among cancer patients with the same diagnosis, and across 
different tumor types43. As such, the potential antigen repertoire is huge, and to a large extend personalized. 
Such levels of complexity are challenging to encompass even with newly developed multiplex T cell detection 
technologies33. b) Tumor-reactive T cells are often functionally compromised due to immunosuppressive 
signals mediated by the tumor. Consequently, such T cells may be difficult to culture and assess in functional 
assays44. c) Tumor-reactive T cells recognizing self-antigens most often comprise T cells having escaped central 
tolerance mechanism. Such T cells would be likely to express TCRs with relatively low affinity for their cognate 
pMHC recognition motif or recognize peptides with a very low MHC affinity. Together, these characteristics 
make it difficult to obtain sufficient TCR pMHC engagement and to generate stable pMHC reagents for T cell 
assessment. d) Finally tumor reactive T cells are most often of low frequency, which hence further challenge 
the detection.   
 
T cell recognition in the context of infectious disease 
In infectious diseases, detection and characterization of antigen specific T cells recognizing common viruses has 
provided important insights to T cell immunology. It is evident, that some viruses seem to partly hijack our 
immune system by occupying large parts our T cell repertoire. It has been shown that CMV-reactivity T cells 
may comprise more than 10% of our bodies T cells in CMV seropositive individuals45,46. Since CMV is a common 
and chronic virus (>80% at age of 30)47, T cell reactivity to this virus can have a great impact on immunological 
ageing and the ability to respond to foreign antigens48,49. In CMV seronegative individuals, other chronic viruses 
seem to take up great fractions of the T cell repertoire, but yet not as dramatically as is observed for CMV. 
Thus, CMV infection should be taken into account as a possible confounder in any immune therapeutic 
strategy, and may be used as a biomarker for responsiveness in certain cases. As an example of their 
therapeutic potential, virus specific T cells have been successfully characterized, in vitro selected and expanded 
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for adoptive transfer strategies, which especially in transplanted patients, can clear otherwise life-threatening 
infections3.   
Virus specific T cells are in general terms easier to detect than T cells in other contexts such as cancer 
responsive or otherwise autoreactive T cells. In studies of T cell responses to viral infection, there is a 
predefined antigen repertoire encoded by the virus genome, and virus responsive T cells are often present in 
detectable frequencies following infections. For chronic viral infections, such T cells are detectable throughout 
life. Studying virus specific T cells has further led to a groundbreaking understanding of T cell development in 
response to both acute and chronic antigen exposure50–52.  
 
Challenges for studies of T cell responses directed at bacteria or viruses with large genomes 
Although many of the best characterized T cell epitopes are derived from viruses with large genomes such as 
EBV or CMV, unbiased screens using multiplex approaches would be particularly challenging for such 
pathogens. Thus, these epitopes have so far been identified through more conventional T cell epitope mapping 
strategies using large cell numbers and/or expanded T cell lines to narrow down antigens with peptide libraries.  
Large screens using enormous peptide libraries, as illustrated for CMV53, have also been very informative in 
understanding the breadth of T cell responses in these instances. Similarly large screens have also been 
performed to identify T cell epitopes in the context of mycobacterium tuberculosis (mTB) infection54.  However, 
typically for such pathogens with large genomes such as mTB, subsets of proteins are targeted based on prior 
knowledge about their relative immunogenicity55 and in this case, the use of peptide-MHC multimers (tetramer 
guided epitope mapping) have also been shown to be useful56. Along these lines, in the study of a rotavirus, 
with a moderately sized genome, large scale screening using combinatorial encoded heavy metal tagged pMHC 
tetramers was used to identify new rotavirus epitopes and to compare the profiles of these cells between 
donors and tissues. In parallel, further analysis of numerous EBV-specific T cell populations showed distinct 
phenotypes of T cells specific for latency vs. lytic cycle EBV antigens57. Thus, although peptide MHC multimer 
based approaches are not necessarily the best place to start when studying bacterial or viral infections with 
pathogens that have large genomes, multiplex approaches can still be leveraged in these settings. 
 
Studies and modulation of self and allergen-specific T cells in autoimmunity and allergy 
More recently, the interrogation of antigen specific T cells has reached the autoimmune and allergy field. In 
allergy, peptide-MHC tetramers and an approach called tetramer-guided epitope mapping (TGEM) has been 
used to identify numerous useful MHC class II restricted antigens58,59. This information has then been leveraged 
in several investigations into the roles of CD4+ T cells in modulating the response to various allergens such as 
nuts, house dust mites and pollen6,60,61. Most autoimmune diseases, including Type I Diabetes (T1D), 
Reumatoid arthritis (RA) and multiple sclerosis (MS) has genetic associations to the MHC gene family, especially 
HLA class II molecules, certainly indicating an HLA class II/CD4 T cell involvement in the pathophysiology. But 
CD8 T cell recognition has been shown to be involved as well62–64. Although limited established knowledge is 
available as to what CD4 and CD8 T cells recognize in these diseases, some progress has been made. In T1D it 
has been shown that insulin, GAD, and proinsulin proteins are targets for T cell recognition, and that the 
presence of such T cells is associated with disease development65–67. In autoimmune diseases the antigens 
targeted by the immune system may also be modified by post translational modifications (PTM) creating neo-
epitopes to which there is no immune tolerance. This has been shown in e.g. T1D67,68, systemic lupus 
erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS)64,69,70. Studies have shown that pre-
diabetic NOD mice have antibodies and effector T cells that react against citrullinated GPR7866, and 
additionally, increased T cell reactivity to citrullinated peptides arising from GAD65 was described in T1D 
subjects65. A recent study in T1D, has identified an alternative open reading frame within human insulin mRNA 
encoding a highly immunogenic polypeptide that is targeted by T cells in T1D patients62, similarly a product 
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from alternative splicing has been demonstrated as frequently recognized by T cells in cancer71. In general, 
studying T cell recognition in autoimmune diseases is challenging due to the lack of defined antigens, the 
unpredictable nature of dysfunctional self-tolerance and intrinsic difficulties in HLA class II epitope mapping 
(See Box 1). Besides diabetes or other diseases where there are some good ideas about the possible targets of 
T cells auto-aggression, real challenges lie ahead for inflammatory diseases where the targets and roles of T cell 
antigen specificity are less well established or may even be triggered without specific antigens involved72. Some 
general aspects of T cell detection challenges in various disease settings are summarized in Table 1. 
 
Challenges in the study of antigen specificity of CD4+ helper T cells 
In general, across various diseases settings, CD8 T cells are more frequently studied than CD4 T cells, since the 
tools available for CD8 T cell analyses and epitope prediction are more robust (further discussed in box 1). This 
partly relates to the structural differences between MHC class I and II molecules. MHC class I has a closed 
conformation, and peptide binding is consequently very restricted in terms of length and anchor positions73, 
allowing for more precise prediction of MHC I binding properties of a given peptide74. On the contrary, MHC 
class II molecules have an open conformation allowing the presented peptide to extend the end of the MHC II 
binding groove. Hence, MHC II peptide binding is less stringent than class I and it is more challenging to 
describe and predict MHC II peptide binding simply due to the greater flexibility in the system75. MHC 
multimers can be generated for both MHC I and II, and used for assessment of both CD8 and CD4 T cells. 
However expression and refolding of MHC II molecules is more demanding than for MHC I and in most cases 
requires expression and purification from insect or mammalian cells76. Additionally, sufficient binding avidity 
between pMHC II multimers and CD4 T cells can be difficult to achieve, and this may be partially related to the 
fact that the CD4 co-receptor provides limited support for the pMHC interactions as compared to the CD8 MHC 
I interaction77,78. This provides additional challenges for T cell detection technologies, such as fluorescent 
labelled MHC multimers, to reach sufficient sensitivity and specificity. Finally, widely-used strategies for 
peptide-exchange of MHC-embedded conditional ligands to generate large libraries of pMHC complexes are so 
far only developed for MHC class I79. The same holds true for di-peptide mediated peptide exchange80 or 
facilitated refolding strategies81. Analogous approaches for MHC class II based on the expression of MHC with 
an enzymatically (e.g., thrombin) cleavable tethered CLIP peptide do allow for relatively high throughput 
production of MHC class II multimers, but this approach seems to only be feasible for some MHC class II alleles. 
HLA-DR and mouse I-E alleles have been used effectively, but this does not seem to work well for HLA-DP, -DQ 
and mouse I-A alleles82,83. 
 
Strategies for dissecting T cell recognition in disease settings 
Interrogation of T cell recognition in a given disease context can either be achieved through direct access to the 
disease mediating T cells – often T cells infiltrating the diseases tissue20,84. These can be analyzed through bulk 
T cell expansion, T cell cloning or T cell receptor identification and re-expression to examine their peptide 
recognition potential. Such strategies can be determined as ‘the direct immunology approach’ where the T cell 
recognition motif is identified through target cell recognition using cDNA library expression, yeast display85,86.   
or target cells of different origin (Figure 2). Alternatively, when no disease-specific T cells are available, these 
can be identified through screening of T cell recognition in diseases relevant settings, using a set of predicted 
antigens selected based in the available pathophysiological knowledge. Numerous T cell epitope mapping 
strategies have been developed to support this ‘indirect immunology approach’ (Figure 2) and each has 
advantages and disadvantages that greatly depend on the disease setting (some are summarized in Table 2). 
Strategies to map the epitope landscape include (but are not limited to) mass-spectrometry-based sequencing 
of eluted peptides, NGS based predictions of e.g. mutation-derived neoepitopes and yeast display approaches 
(Figure 2). Despite ongoing efforts in developing multiplex-approaches, in many instances the range of possible 
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antigens that can be screened will be to too large to be examined using synthesized peptides and peptide-MHC 
multimer libraries. One way to narrow down the candidates is to elute peptides from target cells and use mass 
spectrometry to sequence these peptides32,87,88. Additionally, the potential antigenic repertoire seems to 
contain a variety of peptides currently not covered by these approaches alone, such as e.g. spliced 
peptides89,90. Thus, a combination of experimental techniques as e.g. mass spectrometry, sequencing analyses, 
proteasomal digestions, and other experimental strategies addressing peptide processing as well as constantly 
improved prediction analyses may be necessary to improve the sensitivity for antigen identification. 
 
Detection of antigen specific T cells using soluble-phase MHC multimers 
When candidate target antigens exist or are predicted, MHC-multimer based strategies have evolved to 
efficiently assess T cell reactivity to large peptide libraries. Three strategies for detection of antigen specific T 
cells using soluble-phase MHC multimers are frequently used in epitope discovery project and will be in focus 
here: 
1. Fluorescently-labelled combinatorial encoded MHC multimers (flow cytometry): 
Two approaches were described in 2009, using combinatorial-encoding of fluorescently labeled MHC 
multimers. Both approaches take advantage of the assumption that any given T cell in the cell sample 
will respond to only one of the pMHC molecules in a given library. Thus, each distinct pMHC multimer 
can be assigned with a unique dual color code91 or multivalent code92, which is then used to identify 
the T cells binding to this particular pMHC molecule. When employing the unique dual color code, any 
T cell not matching the pre-determined color combinations is considered as non-responsive to the 
given pMHC multimer. This strategy provides a low limit of detection (0.002%) and an improved 
distinction between background events and specific pMHC binding T cells, compared to single-color 
fluorescent labelling approaches. However, both approaches require that peptide sequences with 
minimal variation are analyzed in separate samples, to avoid cross-recognition between peptides 
within a given sample. This strategy has so far been used to dissect T cell reactivity against up to 45 
different pMHC complexes in a single sample, but with recent progress in the field of muliticolor flow 
cytometry this strategy may easily expand to a higher complexity. Novel flow cytometers allow up to 
50 parameters to be detected simultaneously, and there is an ongoing effort to characterize and design 
new fluorescent molecules to match this complexity. However not all fluorochromes has sufficient 
intensity to be used for tagging of MHC multimer specific T cells. With a hypothesized number of 30 
different fluorochromes available for tagging of MHC multimers, the system using dual color codes 
would allow 420 different T cell specificities to be analyzed in a given samples. Thus, reaching far 
beyond what has previously been implemented using this strategy – and such complexity will certainly 
call for computational analyses the flow cytometry data93. It should be noted, that despite improved 
analyses tools and automated compensation matrixes adjusting for spectral overlap between 
fluorescent molecules, there will be substantial reduction of signal due to spectral overlap in certain 
channels 94. 
 
2. Metal labeled combinatorial encoded MHC multimers using mass cytometry (CyTOF): 
With the emergence of mass cytometry that uses heavy metal ions as tags, there has been a dramatic 
leap in the number of labels that can be applied in parallel compared with fluorescence flow cytometry 
95–97. Combining mass cytometry with combinatorial pMHC tetramer staining using a total of 10 metal 
labels applied in unique combinations of three labels per MHC multimer, has enabled screening for 109 
different antigen-specificities in one sample, while still leaving a substantial number of labels for 
parallel phenotype and functional analysis of T cells57.  Extending this approach with additional metal 
channels dedicated to pMHC tetramers and/or using quadruple combinatorial coding, several hundred 
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tetramers can be used in parallel, while still retaining >20 channels available for profiling of the antigen 
specific cells (unpublished data). As discussed below, mass cytometry based high-dimensional 
assessment of T cell phenotype and function has shown that T cells derived from human blood and 
tissues are remarkably diverse in terms of their protein expression profiles98–101. This high-resolution 
perspective of T cell profile is particularly powerful when combined with the ability to discriminate T 
cells based on antigen specificity. This way, T cells derived from precious tissue such as tumor-
infiltrates can be used without expansion to simultaneously screen-for T cells antigen specificity and to 
deeply profile the antigen-specific cells detected. The disadvantages of mass cytometry as a screening 
platform includes its low efficiency in cells capture (only 40% of the acquired cell will be analyzed) and 
the inability to retrieve these cells after analyses. However, these limitations are slowly improving as 
better strategies are developed for implementing this technology.  
Mass cytometry and the ability to analyze large numbers of proteins at the single cell level 
together with the development of many new high dimensional data analysis methods have led to a 
greater appreciation of the complexity of immune cell heterogeneity in both blood and in tissues98–101.  
In particular, it has been used to expose the great extent of functional heterogeneity that T cells 
possess in both blood and across tissues, and how this relates to the expression of various other 
cellular markers such as trafficking receptors 102–104. Also in various disease settings including mass 
cytometry is being used to more broadly profile changes in cellular composition over the course of 
disease105–107. Thus, it is clear that T cells are incredibly diverse, especially within tissues, and now the 
challenge remains to understand how this diversity is related to the antigen-specificities of these cells 
and how this information can be used to better understand and predict disease outcomes.  
 
3. DNA-barcode labelled MHC multimers (Cell sorting & NGS) 
The most recent addition to the immunologist toolbox for detecting T cells based on antigen 
recognition involves implementation of a new type of label. Instead of using fluorescence or metal 
labels, we have applied unique DNA barcodes that, when attached to MHC multimers, form specific 
tags for the given pMHC epitopes33. DNA barcodes can be designed with a complexity of up to 1010 
different sequences, each forming a unique tag108. As a result, this strategy is not bound by the number 
of available labels, which has previously been the most critical limitation for high-throughput detection 
of antigen-responsive T cells. We have shown that this approach can be applied to screen for more 
than 1,000 specificities in a single sample. The read-out using this technology is fundamentally different 
in that it measures the number of pMHC-TCR interactions rather than the number of specific cells. 
Taking advantage of a common fluorescent label on all pMHC multimers it enables a calculation 
(fraction of specific reads out of total reads x freq. of sorted cells), that estimate of the frequency of 
specific T cells in a given sample33.  
The DNA barcode-based approach offers the advantage that it is less dependent on stringent 
fluorescent-based separation of multimer positive from multimer negative events. The technology 
therefore represents an attractive tool for detecting low avidity TCR:pMHC interactions such as shared 
tumor-associated antigens33.  Such T cells are merely detectable based on fluorescent separation due 
to the limited amount of fluorescent labelled pMHC mutimer binding to their surface. But these T cells 
can still be specifically determined based on their DNA barcode signal. However, this strategy remains 
to prove its potential in terms of identifying T cell recognition as correlated to disease progression or 
response to therapy. The strength for detection of self-antigens may be useful in studying both cancer 
and autoimmune T cell recognition.  
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Additionally, the nature of the tag form an ideal basis for combining pMHC binding with 
sequencing approaches as the DNA barcode tag can be amplified and revealed in any sequencing 
platform upon adaptation. 
 
 
Other MHC-multimer based approaches 
In parallel to the development of the soluble-phase approaches as described above, a number of plate-bound 
or matrix strategies has been developed, likewise to increase the capacity of pMHC-based screenings. Protein-
based microarrays have been developed and combined with pMHC-based capturing of T cells – with pMHC 
mono-or multimers either as the plate-bound protein directly responsible for cell capturing 109–115 or through 
specific probes associating pMHC molecules to a given spot on the microarray. However, the spatial separation 
of T cells may impact the sensitivity of the overall strategy as most such approaches seem to be limited by a 
low sensitivity and reproducibility compared to existing cytometry based analyses. Matrix-based approaches 
have been developed for T cell identification. In this method, a set of MHC multimers are split into matrix-
defined pools, in such a way that no specific MHC multimer are present in all pools. Each multimer pool is used 
to stain an equal number of cell aliquots derived from a given sample. For each pool, TCRβ sequencing is 
applied to both the MHC multimer positive and negative populations following cell sorting, and TCRβ 
clonotypes enriched within the positive population and uniquely identified in pools carrying a given pMHC 
molecule are identified and used to reveal the antigen specificities within the  sample116. A similar approach 
has been used to identify numerous allergy antigens based on CD4 T cell recognition61,117. 
 
Detection of antigen specific T cells based on functional markers  
A number of techniques have been used to determine the functional capacity of antigen specific T cells, and to 
identify target reactive T cells based on a functional readout. These include primarily measures of cytokine 
release either by intracellular cytokine staining (ICS) or ELISPOT (Table 2). More recently the staining of surface 
markers induced by antigen stimulation e.g. CD154 or CD137 has been used to efficiently track antigen 
responding T cells in selected disease settings. However, this strategy does not provide direct information 
about the peptide recognition of the responding T cell population it can provide value information about the 
level of T cell recognition. Ideally, when antigen specific T cells are examined using MHC multimer staining 
additional functional readout should be provided. However, T cell stimulation leads to TCR internalization and 
consequently may at least partially impede such combined investigations. Information about functional 
capacity can be essential to understand the role of pMHC specific T cells in a given disease settings. For 
instance, tumor-infiltrating lymphocytes have been described staining with both, wildtype and mutated MHC-
peptide-multimer30 whereas distinct binding of a defined mutated MHC-peptide-multimer may not necessarily 
exclude wildtype reactivity32. Thus, current technological improvement of large-scale descriptive analyses of T 
cells by MHC multimer technologies should be followed by investigation of T cell function or role in a defined 
clinical context. For in-depth and fully validated characterization of T-cell responses, additional testing systems 
that allow functional analyses, deeper phenotyping and RNAseq are important and may require TCR isolation 
and transduction experiments. 
 
Future perspectives for understanding antigen recognition 
T-cells may recognize and destroy cells presenting non-self-peptides (epitopes) bound to MHC molecules. This 
recognition is mediated by the heterodimeric T-cell receptor (TCR). The number of possible distinct TCRs (here 
αβ TCRs) generated through genetic recombination, has been estimated at ~1015 although the number of 
distinct TCRs in an individual human is probably closer to 107 118,119. Consequently, T-cell recognition is very 
complex, designed to match the complexity of intruding pathogens. Adding to the complexity is the genetic 
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variation in major histocompatibility complex I (MHC I) loci, resulting in a large diversity in MHC expression 
among individuals. Although TCRs appear to be highly restricted in terms of HLA-recognition determined by 
individuals HLA type120,121, a given T cell is capable of recognizing multiple antigens. In fact, estimates suggest 
that each TCR can recognize up to 106 different peptide sequences86,122. Thus, strategies that allow coverage of 
both the complexity of the antigen-landscape and the cross-recognition capabilities of a given TCR, could 
provide novel understanding in terms of the relationship between these two facets. Such information might 
also provide insight into the relationships between infectious agents and autoimmune reactivity, which has for 
many years been suspected to play a role in the development of autoimmune diseases.  
Future strategies should allow for: 
1. Epitope mapping and antigen selection at a genome-wide level 
2. Interrogating the naïve T cell repertoire  
3. Improved target prediction through TCR profiling 
4. T cell recognition patterns beyond distinct antigens 
 
Epitope mapping and antigen selection at a genome-wide level 
The methods currently available to map this complex interaction on a molecular level are poorly matching the 
diversity in immune recognition. Consequently, immune analyses are currently focusing on a panel of model 
antigens that only provides information about a few needles in the total immune haystack. The identification of 
important targets for immune recognition will greatly enhance our ability to combat disease and tissue 
destruction – therefore technologies are needed that significantly extend state of the art to enable a much 
more comprehensive assessment of T cell mediated immunity. 
Prediction of peptide-MHC affinity has become a valuable tool for predicting peptide presentation123, 
but this is only partly describing the potential immunogenicity. Unbiased analyses of peptide presentation and 
their ability to mount immune responses is needed to allow prediction including other parameters than MHC 
binding, which is currently the key component for any such prediction. Characteristics of antigen processing are 
currently not improving prediction of pMHC presentation. Recent progress is being made in developing more 
sensitive mass-spec-based analyses of MHC embedded peptide32,124,125. Such strategies, especially when 
combined with unbiased T cell analyses should significantly improve our ability to predict which peptides will 
be presented at the cell surface, capable of mounting an immune response. 
Improved prediction tools are of particular interest in the field of personalized neoepitope vaccination124,126. 
Neoepitopes are defined based on the patient-specific cancer mutagenome and formulated into a vaccine42. 
However, most available vaccine platforms allow the combination of 2-20 different epitopes in such vaccine 
formulation, and hence require precise prediction tools to hit the target. Currently, limited knowledge is 
available on the immunogenicity of neoepitopes, and consequently prediction algorithms suffer from low 
sensitivity of prediction127,128.  More comprehensive and unbiased full mutagenome-wide analyses of T cell 
recognition would provide valuable data to improve such predictions.  
Current tools allow us to screen for T cell recognition using up to 1000 different pMHC complexes in a single 
sample. For DNA barcode labelled MHC multimers, the tagging system may even allow for much more 
comprehensive screenings.  The maximum library size that can be reached and applied for simultaneous 
screening of T cell recognition has not yet been established using this strategy. Certainly limitation exist in the 
ability of a given T cell to reach all possible pMHC complexes in the mixture and to avoid unspecific binding 
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driven by the CD8 interaction, when pMHC multimer solutions reach very high concentration. Microfluidics 
systems can likely be applied to assure this balance and hence this strategy may even allow for full peptidomics 
screening. 
Of equal importance is our ability to combine T cell specificity analysis with complex phenotyping and 
assessment for functional characteristics. This is currently achieved using the CyTOF-based strategy, which may 
even extend in the future as larger numbers (hundreds are already possible) of pMHC-multimers continue to 
be integrated into this strategy and as mass cytometry approaches improve in terms of throughput, sensitivity 
and cellular recovery. Emerging strategies in the field on single cell analyses and index sorting further allow for 
single cell mRNA expression analyses while protein level of selected parameters can be achieved by flow 
cytometry129. More recent, high-throughput strategies for single cell analyses, such as the drop-seq 
approach130,131 allows for fast and efficient analyses at a single cell level, where antibodies132,133 or pMHC 
molecules33 may be DNA barcoded to obtain specific knowledge on protein expression and T cell specificity 





Interrogating the naïve T cell repertoire  
Additionally, as these highly multiplexed T cell detection technologies become increasingly more sensitive, we 
might reach the ability to interrogate the naïve repertoire, in terms of understanding what naïve T cells from a 
given individual is capable of responding to134. We are not born with equally abilities to fight infections – or risk 
of developing autoimmune diseases. Such variations can partially be explained by the genetic variations in HLA 
expression, but certainly our T cell repertoire plays a central role determining our ability to recognize target 
cells expressing foreign-or modified antigens, as a consequence of infection or malignant transformation.  
However our current tools to interrogate the TCR repertoire is very immature. Novel insight to TCR repertoire 
recognition could significantly improve our ability to design personalised therapies, not only based on 
individual expression patterns but also the patient’s ability to respond to such antigens as determined by their 
T cell repertoire.  Currently, we have no techniques that allow the interrogation of the naïve T cell repertoire in 
a comprehensive fashion. It has been shown that the ability to respond to antigen challenge is dependent on 
the precursor frequency of naïve T cells capable of recognising a given antigen, and that such measure can 
successfully be incorporated in vaccine design, used for selection of epitopes most likely to raise immune 
recognition. But, interrogation of naïve precursor T cell frequencies on the individual level is very labour 
intensive and not feasible for implementation in patient tailored therapies in the current form. The ongoing 
initiatives to target neoepitopes in cancer through therapeutic vaccination is currently challenged by the weak 
prediction of neoepitope immunogenicity, and novel tools providing insight to patients T cell repertoire and the 
ability to respond to certain antigens would significantly increase the chance for selecting effective vaccination 
targets (epitopes)28.  
 
Improved target prediction through TCR profiling 
Despite significant improvement in T cell detection we remain to establish the link between TCR sequence and 
antigen recognition profiling.  Since such interactions are extremely complex, they are expected to be very 
challenging to predict. This calls for improved computational modulations of the TCR pMHC interaction. 
Consequently, large libraries of matched-pairs of TCR-epitope specificity are required to achieve sufficient 
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insight to TCR-based epitope recognition, enabling such computational modulation and ultimately allow 
prediction of epitope recognition motif based on TCR sequence. This is a very tall order but some progress is 
being made 135,136, and strategies for collection of TCR sequence and antigen specificity at a single cell level 
becomes increasingly more efficient. In reverse, yeast-display of peptide-MHC libraries are being used to better 
understand the range of antigens that a given T cell receptor can recognize85.  Recently, two independent 
studies demonstrated the feasibility for assessing the peptide recognition motif of a given TCR and predict the 
diversity the in terms of peptide restriction137,138. Such analysis forms a crucial platform to initiate predictions 
of pMHC restriction based on TCR sequence. Computational models have been developed that allow prediction 
antibody epitopes139, and success from this field encourage immunologist to believe the TCR-based predictions 
will be possible eventually Such strategies would provide a whole new dimension to our immunological 
understanding and our ability to predict T cell recognition.  
 
T cell recognition patterns beyond distinct antigens 
Finally, more sophisticated tools can lead us to a more complete picture or network structure for how the T cell 
repertoires works, and how stimulation with certain antigens during infection can potential impact self-antigen 
recognition through complex cross recognition mechanisms. It requires tools that enable not only a 
comprehensive screening for distinct T cell epitopes, but allow for the analyses of related patterns that such T 
cell profiles may additionally recognize. This will provide landscapes of T cell recognition patterns associated 
with distinct epitope recognition. Strong interaction between experimental immunologist and computational 
experts is required to solve this challenge. The benefit of such T cell recognition networks, will be an improved 
understanding of how immune mediated diseases may co-evolve or impact each other, and how vaccine 
strategies can be tailored to match individual T cell landscapes.  
 
Translation to therapeutic application 
All strategies mentioned above can provide valuable data to determine or predict the T cell responsiveness to a 
given therapeutic intervention and hence serve as a biomarker to guide therapeutic decisions, such as patients 
tailored treatment selection. Dependent on the disease context and HLA types, a patient-specific selection of 
targets can be essential. The extreme personalized strategy is found in the form of neoepitope vaccinations42. 
Additionally the immunocompetence of patients can be extremely important. Age is one parameter important  
for immunocompetance140, and is has been shown that younger individuals  mount stronger immune responses 
following influenza vacations49. But also preexisting immunity provides an important co-factor; as such CMV 
infection in younger individual has been shown to enhance immune responsiveness to additional infections or 
vaccination49. Also post- or during therapy immune evaluations may guide decision making. For certain 
therapies the induction of T cell responses is essential to the therapeutic efficacy, and such T cell responses can 
be measured and may serve as a response to therapy’ biomarker allowing for early signs of clinical response to 
be realized, while non-responding patients may be offered other therapies. Thus such analyses may guide the 
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Autoimmunity Self-antigens In most cases, 
antigens are not 
known and range 
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very large 





Allergy Allergens Restricted to the 
proteins present 
in the allergen 










Table 2. Strategies for dissection of T cell responses. 
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Box 1. Challenges in studying CD4+ T cells with peptide-MHC multimers. 
Just as CD8+ T cells can be identified using MHC class I multimers, CD4+ T cells can be labeled using multimers 
of MHC class II. However, several factors make these studies significantly more challenging. 
MHC class II protein expression. Whereas most MHC class I proteins can be expressed as recombinant proteins 
in bacteria and refolded in the presence of peptide (or conditional peptide)79 ligands, refolding of MHC class II 
proteins is notoriously inefficient. Instead MHC class II are typically expressed using insect152 or mammalian82 
expression systems which are generally more challenging to setup and optimize. 
Variable peptide binding characteristics.  Compared to MHC class I, MHC class II proteins have more diverse 
properties when it comes to binding to peptide ligands. In addition to their wider range of binding motifs, some 
MHC class II alleles can often bind the same peptides in multiple registers (e.g., different parts of the peptide 
being anchored to the MHC) 83,153.  The consequence is that some alleles require the careful design of tethered 
peptide ligands and are therefore not amenable to high throughput production approaches.  This seems to be 
the case especially for human HLA-DP and DQ (mouse I-A) proteins. Some are amenable to peptide exchange 
(e.g., cleavage and release of tethered CLIP peptide) and do allow for higher throughput production (e.g., 
various human HLA-DR alleles and mouse I-E). 
Less predictable peptide binding motifs. Related to the previous point, motifs for peptides binding to MHC 
class II are more complicated and therefore it is more difficult to predict if any given peptide will bind to an 
MHC class II allele of interest154. 
Higher diversity of alleles expressed by human populations. Several MHC class I alleles have conveniently high 
allele frequencies in well-studied human populations. For instance, the HLA-A*0201 and -A*1101 alleles are 
expressed by approximately half of Caucasian and Chinese ethnicity populations, respectively.  In contrast, the 
frequencies of the most common HLA-DR alleles vary more dramatically between various human populations 
and the expression of any given allele in any given population rarely exceeds 30%. 
Low frequency antigen-specific effector and memory CD4+ T cells. Studies in infectious diseases and in allergy 
where peptide-MHC tetramers have been used to identify antigen specific CD4 T cells have highlighted that 
these cells are often found at remarkably low frequencies. This is likely because CD4+ T cells appear to target a 
broader range of peptide antigens (response spread across more different epitopes) and because CD4+ T cell 
responses typically have lower magnitudes in terms of frequencies observed at the peak of the response and in 
terms of the frequencies observed after contraction and memory formation155,156.  
mass 
spectrometry 
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MHC-bound peptides 
to identify candidate T 
cell antigens. 




peptides are difficult to 
detect. 
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recognized by a 
given T cell 
receptor. 
After cloning of T cell 
receptors for T cells of 
interest, recombinant T 
cell receptor proteins 
are produced and used 
to screen large libraries 
of yeast displaying 
peptide-MHCs. 
Possible to identify 
antigens without 
knowing the origin 
of the antigen. 
Low throughput in terms of 
the number of T cells that can 
be analyzed and requires a 






Lower affinity T cells more common. Although MHC class I restricted CD8+ T cells with low affinities for 
antigen have also been reported, low affinity CD4+ T cells are more commonly reported. This may be 
influenced primarily by the lack of CD4 mediated stabilization of the MHC II-TCR complex77,78. Low T cell 
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Figure 1: Antigen processing and T cell recognions strategies. A) a schematic overview of the different pathogens and 
protein modifications leading to potential epitope presentation and T cell recognition in different diseases. B) a schematic 
overview of the three multiplex MHC multimer technologies discussed in depth throughout this perspective, fluorescently 
labeled combinatorial encoded MHC multimers, heavy-metal labeled combinatorial encoded MHC multimers and DNA 
barcode labeled MHC multimers  
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Figure 2: Epitope mapping – gaining insight to disease mechanisms. A generic workflow for T cell epitope mapping 
strategies using either the direct or indirect epitope mapping approach. The workflow address different technology options 
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Figure 3: Moving towards T cell antigen recognition landscapes 
Through the examination of T cell recognition and the identification of antigen profiles of 
relevance one can gain insight to heterogeneity, functionality and phenotype of disease 
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Figure 4: Translation to therapeutic application.  
T cell recognition profiling may be applied before, during and after therapy to guide therapeutic decision making in 
immunotherapeutic strategies based on patient’s immunocompentences and response to therapy. Immune analyses can 
advise the selection of patients tailored therapies and clinical decision making. 
